Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.

Journal of lipid research - 1 Nov 2010

Wojczynski Mary K, Gao Guimin, Borecki Ingrid, Hopkins Paul N, Parnell Laurence, Lai Chao-Qiang, Ordovas Jose M, Chung B Hong, Arnett Donna K

Abstract excerpt

Hypertriglyceridemia, defined as a triglyceride measurement > 150 mg/dl, occurs in up to 34% of adults. Fenofibrate is a commonly used drug to treat hypertriglyceridemia, but response to fenofibrate varies considerably among individuals. We sought to determine if genetic variation in apolipoprotein B (APOB), an essential core of triglyceride-rich lipoprotein formation, may account for some of the inter-individual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoproteins B
Share to APOB gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Hypertriglyceridemia

Share to Polymorphism, Single Nucleotide

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 20724655
DOI: 10.1194/jlr.P001834
PMCID: PMC2952572

Genes

APOB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.PMID 20724655Read ↗

The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.Semantic proximity Read ↗

Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.Semantic proximity Read ↗

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.Semantic proximity Read ↗

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.Semantic proximity Read ↗

A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.Semantic proximity Read ↗

Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.Semantic proximity Read ↗

The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions.Semantic proximity Read ↗

Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.Semantic proximity Read ↗

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.Semantic proximity Read ↗

Common Genetic Variations Involved in the Inter-Individual Variability of Circulating Cholesterol Concentrations in Response to Diets: A Narrative Review of Recent Evidence.Semantic proximity Read ↗

The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.Semantic proximity Read ↗

Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.